BRETEC.HE Bioretec Oy
- Market cap
- EUR 27.9M
- P/E
- -
- P/B
- 1.54x
- ROE
- -97.1%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the fiscal year ending Dec 2025.
Is BRETEC.HE undervalued?
Graham numberThe Graham number of Bioretec Oy cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bioretec Oy fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-52.8%), below 10%.
ROA 0/1
Return on assets (-46.3%) is below the industry median (-8.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-62.6%) is below the industry median (5.4%).
Revenue Growth 1/2
Revenue grew 6.2% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.2 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.5x) is below the industry median (1.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Bioretec Oy stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bioretec Oy
Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide. The company offers Activa IM-Nail, a bioabsorbable option for pediatric forearm intramedullary nailing; ActivaNail, an implant that is be used in upper or lower limbs to ensure successful bone regeneration; ActivaPin, a bioabsorbable implant for upper and lower limb fractures; and Activa…
Full company profileBioretec Oy financial statements
Bioretec Oy annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 1.75M | 1.50M | 2.00M | 2.94M | 3.91M | 4.54M | 3.52M |
| Gross Profit | 1.25M | 1.10M | 1.38M | 2.14M | 2.73M | 3.22M | 2.31M |
| Operating Income | -1.74M | -1.92M | -2.67M | -2.29M | -3.03M | -4.20M | -8.69M |
| EBITDA | -1.58M | -1.77M | -2.50M | -2.11M | -2.73M | -3.87M | -8.36M |
| Net Income | -1.73M | -2.26M | -6.02M | -2.42M | -3.79M | -4.61M | -9.48M |
| EPS | -0.16 | -0.17 | -0.43 | -0.16 | -0.19 | -0.19 | -0.31 |
| Balance Sheet | |||||||
| Total Assets | 1.63M | 3.89M | 8.58M | 3.49M | 10.7M | 11.5M | 11.7M |
| Total Liabilities | 2.90M | 2.53M | 4.24M | 1.57M | 2.43M | 1.74M | 1.92M |
| Shareholders' Equity | -1.26M | 1.36M | 4.34M | 1.92M | 8.23M | 9.74M | 9.76M |
| Cash & Short-term Investments | 58.0K | 2.27M | 6.62M | 1.22M | 6.91M | 6.29M | 4.13M |
| Cash Flow | |||||||
| Operating Cash Flow | -1.22M | -2.00M | -2.39M | -2.36M | -3.44M | -5.11M | -9.76M |
| Capital Expenditure | 0.00 | 0.00 | 393K | 260K | 161K | 729K | 584K |
| Free Cash Flow | -1.22M | -2.00M | -2.78M | -2.62M | -3.60M | -5.84M | -10.3M |
| Ratios | |||||||
| ROE | - | -166.1% | -138.7% | -125.8% | -46.0% | -47.4% | -97.1% |
| ROA | -106.2% | -58.0% | -70.1% | -69.3% | -35.5% | -40.2% | -81.2% |
| Net Profit Margin | -99.3% | -150.7% | -300.4% | -82.1% | -97.0% | -101.5% | -269.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bioretec Oy dividends
Bioretec Oy has not paid dividends in the last 7 fiscal years.
Who owns Bioretec Oy
- Insiders 0.52%
- Institutions 0.61%
- Public & others 98.87%
- Shares outstanding 1.34B
Bioretec Oy company profile
- Company name
- Bioretec Oy
- Ticker
- BRETEC.HE
- Exchange
- Helsinki Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- Yrittäjänkulma 5, Tampere, Finland, 33710
- Phone
- 358 2077 89500
- Website
- bioretec.com
About Bioretec Oy
Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide. The company offers Activa IM-Nail, a bioabsorbable option for pediatric forearm intramedullary nailing; ActivaNail, an implant that is be used in upper or lower limbs to ensure successful bone regeneration; ActivaPin, a bioabsorbable implant for upper and lower limb fractures; and ActivaScrew, an absorbable surgical implant that is used in fracture treatment, osteotomy, arthrodesis, and bone graft surgery. It also provides ActivaScrew Cannulated that offers a range of fully threaded and partially threaded cannulated screws for fixation of fractures and osteotomies; ActivaScrew Interference, a tool for multiple uses regarding bone fractures, osteotomies, arthrodesesm, and bone grafts; ActivaScrew Interference TCP, a biocomposite interference screw; and RemeOs Screw, a magnesium screw implants. The company was formerly known as BCI Bioabsorbable Concepts Oy. The company was incorporated in 1998 and is headquartered in Tampere, Finland.
Bioretec Oy management
4- Ms. Sarah Van Hellenberg Hubar-FisherChief Executive Officer · born 1978
- Mr. Panu Mikkonen M.Sc.Chief Financial Officer
- Mr. Rene EveDirector of Operations
- Mr. Conan CavanaghHead of Research & Development